These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 19898178)
1. Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab. Sheybani A; Kymes S; Schlief S; Apte R Retina; 2009; 29(10):1404-8. PubMed ID: 19898178 [TBL] [Abstract][Full Text] [Related]
2. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA; Retina; 2008; 28(10):1387-94. PubMed ID: 18827735 [TBL] [Abstract][Full Text] [Related]
3. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Wong LJ; Desai RU; Jain A; Feliciano D; Moshfeghi DM; Sanislo SR; Blumenkranz MS Retina; 2008 Oct; 28(8):1151-8. PubMed ID: 18685542 [TBL] [Abstract][Full Text] [Related]
4. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Wickremasinghe SS; Michalova K; Gilhotra J; Guymer RH; Harper CA; Wong TY; Qureshi S Ophthalmology; 2008 Nov; 115(11):1911-5. PubMed ID: 18672291 [TBL] [Abstract][Full Text] [Related]
5. Bilateral intravitreal injection of antivascular endothelial growth factor therapy. Mahajan VB; Elkins KA; Russell SR; Boldt HC; Gehrs KM; Weingeist TA; Stone EM; Abràmoff MD; Liu D; Folk JC Retina; 2011 Jan; 31(1):31-5. PubMed ID: 21187731 [TBL] [Abstract][Full Text] [Related]
6. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations]. Małgorzata F Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123 [TBL] [Abstract][Full Text] [Related]